Acute chest syndrome (ACS) is the leading cause of death in sickle cell disease, accounting for up to 25% of all SCD-related mortality. If you’re here because you or someone you care for has sickle cell disease, here’s what you need to know right now: ACS is a medical emergency that combines lung inflammation, infection, and vaso-occlusion—and recognizing and managing acute chest syndrome in sickle cell disease early can be the difference between a short hospital stay and an ICU admission.
ACS affects roughly 50% of all sickle cell patients at some point in their lives, with the highest incidence in children aged 2–4 years. The mortality rate for a single episode ranges from 1.8% in children to 4.3% in adults, but it climbs sharply when treatment is delayed. Let’s break down exactly what happens, how it’s diagnosed, and what the current evidence says about treatment.
What Exactly Is Acute Chest Syndrome?
ACS is defined by a new pulmonary infiltrate on chest X-ray involving at least one complete lung segment, combined with one or more of the following: chest pain, fever ≥38.5°C (101.3°F), tachypnea, wheezing, cough, or new-onset hypoxemia. Think of it as pneumonia’s more dangerous cousin—it looks similar on imaging but involves sickling of red blood cells within the lung vasculature, creating a vicious cycle of inflammation and oxygen deprivation.
About 50% of ACS episodes actually begin during a hospitalization for a vaso-occlusive pain crisis. That’s a critical clinical pearl: the patient admitted for rib or sternal pain who suddenly develops a cough, drops their oxygen saturation, and spikes a fever on day 2 or 3—that’s classic ACS evolution.
What Causes ACS? The Three Major Triggers
The Cooperative Study of Sickle Cell Disease (the largest multicenter study on ACS, published in the New England Journal of Medicine) identified three primary causes:
| Cause | Frequency | Key Details |
|---|---|---|
| Pulmonary infection | ~30% of cases | Chlamydia pneumoniae, Mycoplasma pneumoniae, and respiratory viruses are the most common. Typical bacteria like Streptococcus pneumoniae also implicated. |
| Fat embolism | ~16% of cases | From bone marrow necrosis during vaso-occlusive crises. Often causes the most severe presentations. |
| Pulmonary infarction | ~16% of cases | Direct sickling within pulmonary vasculature leading to ischemia and tissue death. |
| Unknown/multifactorial | ~38% of cases | No single identifiable cause despite workup—likely a combination of mechanisms. |
Other contributing factors include hypoventilation from rib infarction pain (patients splint and don’t breathe deeply), post-surgical atelectasis, and fluid overload from aggressive IV hydration.
How Is ACS Diagnosed?
Diagnosis requires clinical suspicion plus imaging confirmation. Here’s the standard workup:
- Chest X-ray — The cornerstone. New infiltrate is required for diagnosis. Lower lobes are most commonly involved. Note: infiltrates may lag behind symptoms by 24–48 hours, so a “negative” initial X-ray doesn’t rule it out.
- Pulse oximetry and arterial blood gas — SpO₂ drop of ≥3% from baseline or PaO₂ <60 mmHg is concerning.
- CBC with reticulocyte count — Look for a drop in hemoglobin ≥1 g/dL from baseline and falling platelet count (both are red flags for worsening ACS).
- Blood cultures and sputum cultures — To identify infectious triggers.
- Type and screen — Anticipate transfusion need early.
CT angiography is sometimes used to evaluate for pulmonary embolism, which can mimic or coexist with ACS. Bronchoscopy with bronchoalveolar lavage can identify fat-laden macrophages when fat embolism is suspected, though this is typically reserved for severe or unclear cases.
Managing Acute Chest Syndrome: The Treatment Protocol
Treatment is multimodal and should begin the moment you suspect ACS—don’t wait for culture results or a radiologist’s final read.
1. Oxygen and Respiratory Support
Target SpO₂ ≥95% (or the patient’s known baseline if chronically lower). Start with supplemental oxygen via nasal cannula. Incentive spirometry is not optional—it’s one of the most evidence-backed interventions. The landmark study by Bellet et al. showed that incentive spirometry every 2 hours while awake reduced ACS incidence during pain crises by 50%.
2. Antibiotics
Empiric coverage should include both a third-generation cephalosporin (like ceftriaxone) AND a macrolide (like azithromycin) to cover atypical organisms. This dual coverage is recommended by the American Society of Hematology (ASH) 2020 guidelines for all ACS episodes, regardless of whether infection is initially suspected.
3. Transfusion Therapy
Simple transfusion is appropriate for mild-to-moderate ACS, aiming to raise hemoglobin to 10 g/dL (do not exceed this—hyperviscosity is a real risk). Exchange transfusion (erythrocytapheresis) is indicated for severe ACS: rapidly worsening hypoxemia, multilobar disease, hemoglobin >10 g/dL at baseline, or clinical deterioration despite simple transfusion. The goal is to reduce HbS to <30%.
4. Pain Management
This is where things get tricky. Pain control is essential—uncontrolled pain leads to splinting, atelectasis, and worsening ACS. But opioids cause respiratory depression. The approach: use the lowest effective opioid dose, avoid excessive sedation, monitor respiratory rate and SpO₂ continuously, and pair opioids with NSAIDs (like ketorolac) when safe to reduce total opioid requirements.
5. IV Fluids
Maintain euvolemia—not aggressive hydration. Fluid overload worsens pulmonary edema and ACS. Run IV fluids at maintenance rates unless the patient is clearly dehydrated.
Preventing Recurrent Episodes
Hydroxyurea is the single most important preventive therapy. The MSH trial demonstrated a 50% reduction in ACS episodes with hydroxyurea use. Every sickle cell patient who has had ACS should be on hydroxyurea unless there’s a specific contraindication.
For patients with recurrent ACS despite hydroxyurea, chronic transfusion therapy to maintain HbS <30% is effective. L-glutamine (Endari), approved by the FDA in 2017, also reduces acute complications including ACS. Crizanlizumab (a P-selectin inhibitor) has shown promise in reducing vaso-occlusive crises and is another option in the growing sickle cell pharmacopeia.
Gene therapy and stem cell transplant represent potential cures that eliminate ACS risk entirely, and outcomes data continue to improve rapidly.
When to Go to the Emergency Room
If you have sickle cell disease, go to the ER immediately if you experience:
- Chest pain combined with fever above 101°F (38.3°C)
- New shortness of breath or difficulty breathing
- Oxygen saturation below 95% on a home pulse oximeter
- A pain crisis that suddenly includes cough or breathing difficulty
- Feeling significantly more tired or confused than usual during a crisis
ACS can progress from mild symptoms to respiratory failure within hours. Early treatment dramatically improves outcomes.
Frequently Asked Questions
How quickly does acute chest syndrome develop?
ACS can develop within hours, but it often evolves over 1–3 days. About half of cases start during a hospitalization for a pain crisis, typically appearing on days 2–3. This is why physicians closely monitor hospitalized sickle cell patients for any respiratory changes.
Can you die from acute chest syndrome?
Yes. ACS is the most common cause of death in sickle cell disease. Mortality per episode is approximately 1.8% in children and 4.3% in adults. However, with prompt recognition and aggressive treatment—especially exchange transfusion for severe cases—most patients recover fully.
What’s the difference between ACS and pneumonia?
They overlap significantly—infection causes about 30% of ACS cases, so ACS can literally include pneumonia. The key difference is that ACS also involves sickling within lung blood vessels, which means standard pneumonia treatment alone isn’t sufficient. ACS requires transfusion support, aggressive incentive spirometry, and careful fluid management in addition to antibiotics.
Can ACS be prevented?
Yes. Hydroxyurea reduces ACS episodes by approximately 50%. Incentive spirometry during every pain crisis hospitalization cuts risk significantly. Pneumococcal and influenza vaccines help prevent infection-triggered episodes. For patients with recurrent ACS, chronic transfusion programs or newer therapies like crizanlizumab may be appropriate.
Is acute chest syndrome the same as a sickle cell crisis?
Not exactly. A “sickle cell crisis” usually refers to a vaso-occlusive pain crisis, which can occur anywhere in the body. ACS is specifically a crisis involving the lungs. However, ACS frequently develops as a complication of a pain crisis—so one can lead to the other.
